Clinical trial
Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in…
NCT00171106 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171106 |
|---|---|
| Title | Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure |
| Official title | A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diastolic Dysfunction, Symptomatic Heart Failure |
| Intervention type | Drug |
| Interventions | valsartan |
| Enrollment | 150 |
| Start date | Dec 1, 2002 |
| Primary completion | Aug 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: